|Bid||31.30 x 100|
|Ask||35.88 x 100|
|Day's Range||32.38 - 33.49|
|52 Week Range||17.50 - 41.57|
|PE Ratio (TTM)||17.46|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Myriad Genetics' (MYGN) year over year decline in revenue was in Q2 is disappointing. However, strong demand for GeneSight tests was encouraging.
The Salt Lake City-based company said it had net income of 45 cents per share. Earnings, adjusted for one-time gains and costs, were 31 cents per share. The results surpassed Wall Street expectations. ...
On Tuesday, Myriad Genetics (NASDAQ: MYGN ) will release its latest earnings report. Benzinga's outlook for Myriad Genetics is included in the following report. Earnings and Revenue Based on management's ...
Shares of the molecular diagnostics name Myriad Genetics (NYSE: MYGN ) are worth less than what the Street is paying, according to Goldman Sachs. The Analyst Goldman Sachs analyst Patrick Donnelly initiated ...
Myriad (MYGN) positioned to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Myriad Genetics (MYGN) has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx test and strengthen the Molecular Diagnostics portfolio.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding MYGN totaled $830 million.
Inogen's (INGN) expanding product portfolio is a key catalyst. Foreign exchange headwinds continue to hurt the company's growth trajectory.
Myriad Genetics (MYGN) has predicted Vectra DA’s annual revenues to reach $100 million in the case of updated ACR guidelines and full reimbursement.
In the first quarter of fiscal 2018, Myriad Genetics’ (MYGN) Vectra DA test reported revenues close to $16 million.
Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.